WO2003012082A2 - Method for modulating stem cell differentiation using stem loop rna - Google Patents
Method for modulating stem cell differentiation using stem loop rna Download PDFInfo
- Publication number
- WO2003012082A2 WO2003012082A2 PCT/GB2002/003409 GB0203409W WO03012082A2 WO 2003012082 A2 WO2003012082 A2 WO 2003012082A2 GB 0203409 W GB0203409 W GB 0203409W WO 03012082 A2 WO03012082 A2 WO 03012082A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- nucleic acid
- rna molecule
- rna
- stem
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
Definitions
- the invention relates to a method to modulate stem cell differentiation comprising introducing stem loop containing RNA into a stem cell to ablate mRNA's which encode polypeptides which are involved in stem cell differentiation; stem loop RNA's ; and nucleic acid molecules and vectors encoding stem loop RNA's.
- anti-sense nucleic acid molecules to bind to and thereby block or inactivate target mRNA molecules is an effective means to inhibit the production of gene products.
- This is typically very effective in plants where anti-sense technology produces a number of striking phenotypic characteristics.
- antisense is variable leading to the need to screen many, sometimes hundreds of, transgenic organisms carrying one or more copies of an antisense transgene to ensure that the phenotype is indeed truly linked to the antisense transgene expression.
- Antisense techniques not necessarily involving the production of stable transfectants, have been applied to cells in culture, with variable results.
- RNAi double stranded RNA
- the RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule.
- the RNAi molecule is typically derived from exonic or coding sequence of the gene which is to be ablated.
- RNAi RNA-binding protein
- the site of action appears to be nuclear as little if any RNAi is detectable in the cytoplasm of cells indicating that RNAi exerts its effect during mRNA synthesis or processing.
- RNAi action is unknown although there are theories to explain this phenomenon.
- all organisms have evolved protective mechanisms to limit the effects of exogenous gene expression.
- a virus often causes deleterious effects on the organism it infects.
- Viral gene expression and/or replication- therefore needs to be repressed, hi addition, the rapid development of genetic transfo ⁇ nation and the provision of transgenic plants and animals has led to the realisation that transgenes are also recognised as foreign nucleic acid and subjected to phenomena variously called quelling (Singer and Selker, 1995), gene silencing (Matzke and Matzke, 1998) , and co-suppression (Stam et. al., 2000).
- RNAi may also function in higher eukaryotes. For example, it has been shown that RNAi can ablate c-mos in a mouse ooctye and also E-cadherin in a mouse preimplanation embryo (Wianny and Zernicka-Goetz, 2000).
- RNAi ablate stem cell RNA
- WO 02/16620 The use of RNAi to ablate stem cell RNA is disclosed in our co-pending application, WO 02/16620, which is incorporated by reference.
- those cells that form part of the embryo up until the formation of the blastocyst are said to be totipotent (e.g. each cell has the developmental potential to form a complete embryo and all the cells required to support the growth and development of said embryo).
- the cells that comprise the inner cell mass are said to be pluripotential (e.g. each cell has the developmental potential to form a variety of tissues).
- Embryonic stem cells may be principally derived from two embryonic sources.
- Cells isolated from the inner cell mass are termed embryonic stem (ES) cells, i the laboratory mouse, similar cells can be derived from the culture of primordial germ cells isolated from the mesenteries or genital ridges of days 8.5-12.5 post coitum embryos. These would ultimately differentiate into germ cells and are referred to as embryonic germ cells (EG cells).
- ES embryonic stem
- EG cells embryonic germ cells
- Each of these types of pluripotential cell has a similar developmental potential with respect to differentiation into alternate cell types, but possible differences in behaviour (eg with respect to imprinting) have led to these cells to be distinguished from one another .
- ES/EG cell cultures have well defined characteristics. These include, but are not limited to;
- ES/EG cells A feature of ES/EG cells is that, in the presence of fibroblast feeder layers, they retain the ability to divide in an undifferentiated state for several generations. If the feeder layers are removed then the cells differentiate. The differentiation is often to neurones or muscle cells but the exact mechanism by which this occurs and its control remain unsolved.
- ES/EG cells hi addition to ES/EG cells a number of adult tissues contain cells with stem cell characteristics. Typically these cells, although retaining the ability to differentiate into different cell types, do not have the pluripotential characteristics of ES/EG cells.
- haemopoietic stem cells have the potential to form all the cells of the haemopoietic system (red blood cells, macrophages, basophils, eosinophils etc). All of nerve tissue, skin and muscle retain pools of cells with stem cell potential. Therefore, in addition to the use of embryonic stem cells in developmental biology, there are also adult stem cells which may also have utility with respect to determimng the factors which govern cell differentiation. .
- stem cells previously thought to be committed to a single fate, (e.g neurons) may indeed possess considerable pluripotentcy in certain situations.
- Neural stem cells have recently been shown to chimerise a mouse embryo and form a wide range of non-neural tissue (Clark et. al., 2000).
- a further group of cells which have relevance to developmental biology are pluripotent embryonal carcinoma cells (EC cells) which are stem cells of teratocarcinomas, also referred to as teratomas, which are able to differentiate into all cell types found in these tumours.
- EC cells pluripotent embryonal carcinoma cells
- a teratocarcinoma also includes teratocarcinoma cells which do not have the full pluripotential characteristics of an EC cell but nevertheless can differentiate into a restricted number of differentiated tissues. These cells have many features in common with ES/EG cells. The most important of these features is the characteristic of pluripotentiality.
- Teratomas contain a wide range of differentiated tissues, and have been known in humans for many hundreds of years. They typically occur as gonadal tumours of both men and women. The gonadal forms of these tumours are generally believed to originate from germ cells, and the extra gonadal forms, which typically have the same range of tissues, are thought to arise from germ cells that have migrated incorrectly during embryogenesis. Teratomas are therefore generally classed as germ cell tumours which encompasses a number of different types of cancer. These include seminoma, embryonal carcinoma, yolk sac carcinoma and choriocarcinoma.
- genes are required for differentiation to occur along specific pathways e.g. the myo genie gene MyoDl.
- Other genes have activity which inhibits cellular differentiation along particular pathways.
- stem cell differentiation to yield a specific cell type could be achieved by:
- RNAi molecules homologous to genes encoding factors involved in stem cell differentiation.
- the differentiation of stem cells during embryogenesis, during tissue renewal in the adult and wound repair is under very stringent regulation; aberrations in this regulation underlie the formation of birth defects during development and are thought to underlie cancer formation in adults.
- stem cells are under both positive and negative regulation which allows a fine degree of control over the process of cell proliferation and cell differentiation: excess proliferation at the expense of cell differentiation can lead to the formation of an expanding mass of tissue - a cancer - whereas express differentiation at the expense of proliferation can lead to the loss of stem cells and production of too little differentiated tissue in the long term, and especially the loss of regenerative potential.
- genes have already been identified to have a negative role in preventing stem cell differentiation. Such genes, like those of the Notch family, when mutated to acquire activity can inhibit differentiation; such mutant genes act as oncogenes. On the contrary, loss of function of such genes on their inhibition results in stem cell differentiation.
- EC cells has a model cell system to follow the effects of perturbations in stem cell differentiation.
- the invention relates to the provision of stem-loop RNA structures which can either be synthesised in vitro followed by transfection into a stem cell, or alternatively, synthesised in vivo by the stem cell from vectors which are provided with expression cassettes which include a DNA molecule which includes the coding sequence for the stem-loop RNA.
- the DNA molecule encoding the stem-loop RNA is constructed in two parts, a first part which is derived from a gene the regulation of which is desired.
- the second part is provided with a DNA sequence which is complementary to the sequence of the first part.
- the cassette is typically under the control of a promoter which transcribes the DNA into RNA.
- the complementary nature of the first and second parts of the RNA molecule results in base pairing over at least part of the length of the RNA molecule to form a double stranded hairpin RNA structure or stem-loop.
- the first and second parts can be provided with a linker sequence.
- nucleic acid molecule comprising a sequence of a gene which mediates at least one step in the differentiation of said cell which nucleic acid molecule consists of a first part linked to a second part wherein said first and second parts are complementary over at least part of their length and further wherein said first and second parts form a double stranded region by complementary base pairing over at least part of their length; (ii) providing conditions conducive to the growth and differentiation of the cell treated in (i) above; and optionally (iii) maintaining and/or storing the cell in a differentiated state.
- said first and second parts are linked by at least one nucleotide base.
- first and second sequences which are complementary to one another and which comprise at least part of the coding sequence of a gene involved in stem cell differentiation means that when the sequence is transcribed into RNA the complementarity between first and second sequences allows base pairing between first and second sequences to form a double stranded RNA structure, see Figure 1.
- the optional provision of a linking region bewteen first and second parts results in the formation of a so called "hair-pin" loop structure.
- the transcription of the nucleic acid provides many copies of the hair-pin loop RNA which effectively functions as a RNAi molecule.
- said nucleic acid molecule is a stem loop RNA molecule.
- said nucleic acid molecule is a DNA molecule which encodes said stem loop RNA.
- said DNA molecule is a vector adapted for expression of said stem loop RNA.
- the stem cell in (i) above may be a teratocarcinoma cell.
- said conditions are in vitro cell culture conditions.
- said stem cell is selected from: pluripotent stem cells such as embryonic stem cell; embryonic germ cell and embryonal carcinoma cells; and lineage restricted stem cells such as, but not restricted to; haemopoietic stem cell; muscle stem cell; nerve stem cell; skin dermal sheath stem cell; liver stem cell; and teratocarcinoma cells.
- pluripotent stem cells such as embryonic stem cell; embryonic germ cell and embryonal carcinoma cells
- lineage restricted stem cells such as, but not restricted to; haemopoietic stem cell; muscle stem cell; nerve stem cell; skin dermal sheath stem cell; liver stem cell; and teratocarcinoma cells.
- stem cells of intermediate commitment For example, embryonic stem cells could be programmed to differentiate into haemopoietic stems cells with a restricted commitment. Alternatively, differentiated cells or stem cells of intermediate commitment could be reprogrammed to a more pluripotential state from which other differentiated cell lineages can be derived.
- said stem cell is an embryonic stem cell or embryonic germ cell.
- said stem loop RNA molecule is derived from a gene which encodes a cell surface receptor expressed by a stem cell.
- said cell surface receptor is selected from: human Notch l(hNotch 1); hNotch 2; hNotch 3; hNotch 4; TLE-1; TLE-2;
- stem loop RNA molecule is derived from a gene which encodes a ligand.
- a ligand is a polypeptide which binds to a cognate receptor to induce or inhibit an intracellular or intercellular response.
- Ligands may be soluble or membrane bound.
- said ligand is selected from: DI M; D113; D114; Dlk-1; Jagged 1; Jagged 2; Wnt 1; Wnt 2; Wnt 2b; Wnt 3; Wnt 3a; Wnt5a; Wnt6; Wnt7a; Wnt7b; Wnt ⁇ a; Wnt8b; WntlOb; W tll; Wntl4; Wntl5.
- said gene is selected from: SFRP1; SFRP2; SFRP4; SFRP5; SK; DKK3; CER1; WIF-1; DVL1; DVL2; DVL3; DVLlLl;mFringe; lFringe; rFringe; selll; Numb; LNX Oct4;NeuroDl; NeuroD2; NeuroD3; Brachyury; MDFI.
- stem loop RNA molecule is derived from at least one of the sequences identified in Table 4 or Figures 4-54.
- said sequence is derived from Oct 4.
- the Oct 4 sequence corresponds to nucleotide sequence about 610 to about 1032 of the Oct 4 sequence found in GenBank accession number NM_ 002701.
- Methods to introduce nucleic acid into cells typically involve the use of chemical reagents, cationic lipids or physical methods.
- Chemical methods which facilitate the uptake of DNA by cells include the use of DEAE -Dextran ( Vaheri and Pagano
- DEAE-dextran is a negatively charged cation which associates and introduces the nucleic acid into cells.
- Calcium phosphate is also a commonly used chemical agent which when co-precipitated with nucleic acid introduces the nucleic acid into cells (Graham et al Virology (1973) 52: p456).
- cationic lipids eg liposomes ( Feigner (1987) Proc.Natl.Acad.Sci USA, 84:p7413) has become a common method.
- the cationic head of the lipid associates with the negatively charged nucleic acid backbone to be introduced.
- the lipid nucleic acid complex associates with the cell membrane and fuses with the cell to introduce the associated nucleic acid into the cell.
- Liposome mediated nucleic acid transfer has several advantages over existing methods. For example, cells which are recalcitrant to traditional chemical methods are more easily transfected using liposome mediated transfer.
- RNAi's can be enhanced by association or linkage of the RNAi to specific antibodies, ligands or receptors.
- kits which purport to provide high efficiency transfection of cells.
- a kit which is particularly preferred is sold under the tradename ExGen SOO 4 " 1 by MBI Fermentas, Lithuania.
- ExGen is a polyethylenimine, non-liposomal transfection reagent.
- a stem loop RNA molecule derived from a coding sequence of at least one gene involved in stem cell differentiation comprising a first part linked to a second part wherein said first and second parts are complementary over at least part of their length and further wherein, said first and second parts form a double stranded region by complementary base pairing over at least part of their length.
- said first and second parts are linked by at least one nucleotide base.
- said first and second parts are linked by 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide bases.
- said linker is at least 10 nucleotide bases.
- said coding sequence is an exon.
- RNA molecule is derived from intronic sequences or the 5' and/or 3' non-coding sequences which flank coding/exon sequences of genes which mediate stem cell differentiation.
- the length of the RNA molecule is between 10 nucleotide bases (nb) -lOOOnb. More preferably still the length of the RNA molecule is selected from lOnb; 20nb; 30nb; 40nb; 50nb; 60nb; 70nb; 80nb; 90nb. More preferably still said RNA molecule is 21nb in length.
- said RNA molecule is lOOnb; 200nb; 300nb; 400nb; 500nb; 600nb; 700nb; 800nb; 900nb; or lOOOnb. More preferably still said RNA molecule is at least lOOOnb.
- RNA molecule comprises sequences identified in Table 4 or Figures 4-54.
- RNA molecules comprise modified nucleotide bases.
- modified bases may confer advantageous properties on RNA molecules containing said modified bases.
- modified bases may increase the stability of the RNA molecule thereby reducing the amount required to produce a desired effect.
- the provision of modified bases may also provide stem-loop structures which are more or less stable.
- nucleic acid molecule encoding at least part of a gene which mediates at least one step in stem cell differentiation comprising a first part linked to a second part which first and second parts are complementary over at least part of their length, wherein said nucleic acid molecule is operably linked to at least one further nucleic acid molecule capable of promoting transcription of said nucleic acid linked thereto and further wherein said first and second parts form a double stranded region by complementary base pairing over at least part of their length as or when said nucleic acid molecule is transcribed.
- RNA molecules which form RNA stem loops can be achieved by providing vectors which include target genes, or fragments of target genes, operably linked to promoter sequences.
- promoter sequences are phage RNA polymerase promoters (eg T7, T3, SP6).
- Advantageously vectors are provided with multiple cloning sites into which genes or gene fragments can be subcloned.
- vectors are engineered so that phage promoters flank multiple cloning sites containing the gene of interest.
- target genes or fragments of target genes can be fused directly to phage promoters by creating chimeric promoter/gene fusions via oligo synthesising technology. Constructs thus created can be easily amplified by polymerase chain reaction to provide templates for the manufacture of RNA molecules comprising stem loop RNA's.
- a vector including an expression cassette comprising a first sequence linked to a second sequence wherein said first and second sequences are complementary over at least part of their lengths and further wherein the expression cassette is transciptionally linked to a promoter sequence.
- said first and second parts are linked by linking nucleotides as hereinbefore described.
- Vectors including expression cassettes encoding stem-loop RNA's are adapted for eukaryotic gene expression.
- said adaptation includes, by example and not by way of limitation, the provision of transcription control sequences (promoter sequences) which mediate cell/tissue specific expression.
- promoter sequences may be cell/tissue specific, inducible or constitutive.
- Promoter elements typically also include so called TATA box and RNA polymerase initiation selection sequences which function to select a site of transcription initiation. These sequences also bind polypeptides which function, inter alia, to facilitate transcription initiation selection by RNA polymerase.
- Adaptations also include the provision of selectable markers and autonomous replication sequences which both facilitate the maintenance of said vector in either the eukaryotic cell or prokaryotic host.
- Vectors which are maintained autonomously are referred to as episomal vectors.
- Further adaptations which facilitate the expression of vector encoded genes include the provision of transcription termination sequences.
- a cell transfected with the nucleic acid or vector according to the invention is provided.
- said cell is an embryonic stem cell or embryonic germ cell.
- said cell is an embryonal carcinoma cell.
- stem loop RNA molecules comprising:
- said gene, or gene fragment is selected from those genes represented in table 4 or Figures 4-54.
- Kits are commercially available which provide vectors, ribonucleoside triphosphates, buffers, Rnase inhibitors, RNA polymersases (eg phage T7, T3, SP6) which facilitate the production of RNA.
- an in vivo method to promote the differentiation of stem cells comprising administering to an animal an effective amount of stem loop RNA molecule, or vector encoding a stem loop RNA molecule according to the invention, sufficient to effect differentiation of a target stem cell.
- Preferably said method promotes differentiation in vivo of endogenous stem cells to repair tissue damage in situ.
- stem loop RNA relies on homology between the target gene RNA and double stranded region of the stem loop in a similar way to conventional RNAi. This confers a significant degree of specificity to the stem loop RNA molecule in targeting stem cells.
- haemopoietic stem cells are found in bone marrow and stem loop RNA molecules may be administered to an animal by direct injection into bone marrow tissue.
- Stem loop RNA molecules may be encapsulated in liposomes to provide protection from an animals immune system and/or nucleases present in an animals serum.
- Liposomes are lipid based vesicles which encapsulate a selected therapeutic agent which is then introduced into a patient.
- the liposome is manufactured either from pure phospholipid or a mixture of phospholipid and phosphoglyceride.
- liposomes can be manufactured with diameters of less than 200nm, this enables them to be intravenously injected and able to pass through the pulmonary capillary bed.
- biochemical nature of liposomes confers permeability across blood vessel membranes to gain access to selected tissues. Liposomes do have a relatively short half-life. So called STEALTH R liposomes have been developed which comprise liposomes coated in polyethylene glycol (PEG).
- the PEG treated liposomes have a significantly increased half-life when administered intravenously to a patient.
- STEALTH R liposomes show reduced uptake in the reticuloendothelial system and enhanced accumulation selected tissues.
- so called immuno-liposomes have been develop which combine lipid based vesicles with an antibody or antibodies, to increase the specificity of the delivery of the RNAi molecule to a selected cell/tissue.
- liposomes as delivery means is described in US5580575 and US 5542935.
- stem loop RNA molecules can be provided in the form of an oral or nasal spray, an aerosol, suspension, emulsion, and/or eye drop fluid.
- the stem loop RNA molecules may be provided in tablet form.
- Alternative delivery means include inhalers or nebulisers.
- a therapeutic composition comprising a stem loop RNA molecule according to the invention or a vector encoding a stem loop RNA according to the invention.
- said stem loop RNA molecule or vector is for use in the manufacture of a medicament for use in promoting the differentiation of stem cells to provide differentiated cells/tissues to treat diseases where cell/tissues are destroyed by said disease.
- differentiated stem cells may be used to replace nerves damaged as a consequence of (eg replacement of spinal cord tissue).
- said therapeutic composition further comprises a diluent, carrier or excipient.
- a cell obtainable by the method according to the invention has useful applications .
- a stably transfected cell under the control of a regulatable promoter ie inducible, repressible, developmentally regulated, cell lineage regulated, cell-cycle regulated
- a regulatable promoter ie inducible, repressible, developmentally regulated, cell lineage regulated, cell-cycle regulated
- At least one organ comprising at least one cell obtainable by the method according to the invention.
- a non-human transgenic animal comprising a RNA molecule according to the invention, or a nucleic acid molecule according to the invention, or a vector according to the invention.
- Table 1 represents a selection of antibodies used to monitor stem cell differentiation
- Table 2 represents nucleic acid probes used to assess mRNA markers of stem differentiation
- Table 3 represents protein markers of stem cell differentiation
- Table 4 represents specific primers used to generate stem loop RNA for gene specific inhibition
- Table 5 represents vectors used for the expression of stem loop RNA in cells including the promoters used to drive transcription of stem loop RNA's.
- Figure 1 illustrates stem cell differentiation is controlled by positive and negative regulators (A).
- the specific cell phenotypes that are derived are a direct result of positive and negative regulators which activate or suppress particular differentiation events.
- Stem loop RNA can be used to control both the initial differentiation of stem cells (A) and the ultimate fate of the differentiated cells Dl and D2 by repression of positive activators which would normally promote a particular cell fate;
- Figure 2 represents the Oct 4 nucleic acid sequence from position 610-1032 of the sequence found in GenBank accession number NM_002701.
- Fig 3A illustrates a transcription cassette comprising a promoter sequence operable linked to a nucleic acid encoding a stem loop RNA
- Fig 3B illustrates a stem loop RNA synthesised from the cassette illustrated in Fig 1 A;
- Figure 4 is the nucleic acid sequence of murine notch ligand delta-like 1 ;
- Figure 5 is the nucleic acid sequence of murine notch ligand jagged 1
- Figure 6 is the nucleic acid sequence of human notch ligand jagged 1 (alagiUe syndrome) (JAG1);
- Figure 7 is the nucleic acid sequence of human notch ligand jagged 2 (JAG2)
- Figure 8 is the nucleic acid sequence of murine notch ligand jagged 2;
- Figure 9 is the nucleic acid sequence of human notch ligand delta-like 3 (DLL3);
- Figure 10 is the nucleic acid sequence of human notch ligand delta-1 (DLLl);
- Figure 11 is the nucleic acid sequence of human notch ligand delta-like 4 (DLL4)
- Figure 12 is the nucleic acid sequence of murine notch ligand delta-like 4(DLL4)
- Figure 13 represents the nucleic acid sequence of human Wnt 13
- Figure 14 represents the nucleic acid sequence of human dickkopfl
- Figure 15 represents the nucleic acid sequence of human dickkopf2
- Figure 16 represents the nucleic acid sequence of human dickkop ⁇
- Figure 17 represents the nucleic acid sequence of human dickkopfl
- Figure 18 represents the nucleic acid sequence of WNT-1
- Figure 19 represents the nucleic acid sequence of WNT-2
- Figure 20 represents the nucleic acid sequence of WNT 2B
- Figure 21 represents the nucleic acid sequence of WNT 3;
- Figure 22 represents the nucleic acid sequence of WNT 4.
- Figure 23 represents the nucleic acid sequence of WNT 5 A
- Figure 24 represents the nucleic acid sequence of WNT 6
- Figure 25 represents the nucleic acid sequence of WNT 7A
- Figure 26 represents the nucleic acid sequence of WNT 8B
- Figure 27 represents the nucleic acid sequence of WNT 10B
- Figure 28 represents the nucleic acid sequence of WNT 11;
- Figure 29 represents the .nucleic acid sequence of WNT 14
- Figure 30 represents the nucleic acid sequence of WNT 16.
- Figure 31 represents the nucleic acid sequence of FZD 1;
- Figure 32 represents the nucleic acid sequence of FZD 2
- Figure 33 represents the nucleic acid sequence of FZE 3
- Figure 34 represents the nucleic acid sequence of FZD 4.
- Figure 35 represents the nucleic acid sequence of FZD 5;
- Figure 36 represents the nucleic acid sequence of FZD 6
- Figure 37 represents the nucleic acid sequence of FZD 7;
- Figure 38 represents the nucleic acid sequence of FZD 8
- Figure 39 represents the nucleic acid sequence of FZD 9;
- Figure 40 represents the nucleic acid sequence of FZD 10
- Figure 41 represents the nucleic acid sequence of FRP
- Figure 42 represents the nucleic acid sequence of SARP 1;
- Figure 43 represents the nucleic acid sequence of SARP 2
- Figure 44 represents the nucleic acid sequence of FRZB
- Figure 45 represents the nucleic acid sequence of FRPHE
- Figure 46 represents the nucleic acid sequence of SARP 3
- Figure 47 represents the nucleic acid sequence of CER 1;
- Figure 48 represents the nucleic acid sequence of DKK1
- Figure 49 represents the nucleic acid sequence of DKK 2;
- Figure 50 represents the nucleic acid sequence of DKK 3;
- Figure 51 represents the nucleic acid sequence of DKK 4;
- Figure 52 represents the nucleic acid sequence of WIF-1;
- Figure 53 represents the nucleic acid sequence of SRFP 1
- Figure 54 represents the nucleic acid sequence of SRFP 4.
- NTERA2 and 2102Ep human EC cell lines were maintained at high cell density as previously described (Andrews et al 1982, 1984b), in DMEM (high glucose formulation) (DMEM)(GTBCO BRL), supplemented with 10% v/v bovine foetal calf serum (GTBCO BRL), under a humidified atmosphere with 10% CO 2 in air.
- Primers were designed against specific target genes with T7 bacteriophage promoters at their 5' ends .
- the primers consist of typically 18- 25 bp against the target gene, a linker sequence of variable length (indicated by N in primer sequence) followed by the reverse complement of the gene specific sequence.
- the primers were used in a standard RNA in vitro, transcription reaction using a MEGASCRIPT kit following manufacturers protocols (Ambion, USA).
- Longer siRNA templates were produced buy cloning head-to -tail the sense and anti-sense gene specific sequences to generate a palindromic template from which RNA could be synthesized.
- Human EC stem cells were seeded at 2 XI 0 5 cells/well of a 6 well plate in 3 cm 3 of Dulbecco's modified Eagles medium and allowed to settle for 3 hrs. Appx. 9.5 ⁇ g of DNA was incubated with an optimised amount of ExGEN 500 for each well of a 6-well plate. Previously cells were seeded 1 day before. This gives apprx. a 70% confluent culture. The DNA/ExGen mixture was added to the cells and the culture vessel spun at 280g for 5 mins.
- RNA production Growing cultures of cells were aspirated to remove the DME and foetal calf serum. Trace amounts of foetal calf serum was removed by washing in Phosphate-buffered saline. Fresh PBS was added to the cells and the cells were dislodged from the culture vessel using acid washed glass beads. The resulting cell suspension was centrifuged at 300xg. The pellets had the PBS aspirated from them. Tri reagent (Sigma, USA) was added at 1ml per 10 7 cells and allowed to stand for 10 mins at room temperature. The lysate from this reaction was centrifuged at 12000 x g for 15 minutes at 4°C.
- RNA was pelleted by centrifugation at 12000 x g for 10 mins at 4°C. The supernatant was removed and the pellet washed in 70% ethanol. The washed RNA was dissolved in DEPC treated double-distilled water.
- stem loop RNA Following exposure to stem loop RNA corresponding to specific key regulatory genes, the subsequent differentiation of the EC cells was monitored in a variety of ways. One approach was to monitor the disapearance of typical markers of the stem cell phenotype; the other was to monitor the appearance of markers pertinent to the specific lineages induced. The relevant markers included surface antigens, mRNA species and specific proteins.
- Cells were treated with trypsin (0.25% v/v) for 5 mins to disaggregate the cells; they were washed and re-suspended to 2x10 5 cells/ml. This cell suspension was incubated with 50 ⁇ l of primary antibody in a 96 well plate on a rotary shaker for 1 hour at 4°C. Supernatant from a myeloma cell line P3X63Ag8, was used as a negative control. The 96 well plate was centrifuged at lOOrpm for 3 minutes. The plate was washed 3 times with PBS containing 5% foetal calf serum to remove unbound antibody.
- RNA separation relies on the generally the same principles as standard DNA but with some concessions to the tendancy of RNA to hybridise with itself or other RNA molecules.
- Formaldehyde is used in the gel matrix to react with the amine groups of the RNA and form Schiff bases.
- Purified RNA is ran out using standard agarose gel electrophresis. For most RNA a 1% agarose gel is sufficiant. The agarose is made in IX MOPS buffer and supplemeted with 0.66M formaldehyde.Dryed down RNA samples are reconstituted and denatured in RNA loading buffer and loaded into the gel. Gels are run out for apprx. 3 hrs (until the dye front is 3/4 of the way down the gel).
- the major problem with obtaining clean blotting using RNA is the presence of formaldehyde.
- the run out gel was soaked in distilled water for 20 mins with 4 changes, to remove the formaldehyde from the matrix.
- the transfer assembly was assembled in exactly the same fashion as for DNA (Southern) blotting.
- the transfer buffer used was 10X SSPE. Gels were transfered overnight.
- the membrane was soaked in 2X SSPE to remove any agarose from the transfer assembly and the RNA was fixed to the memebrane. Fixation was acheived using short-wave (254 nM) UV light.
- the fixed membrane was baked for 1-2 hrs to drive off any residual formaldehyde.
- Hybridisation was acheived in aqueous phase with formamide to lower the hybridisation temperatures for a given probe.
- RNA blots were prehybridised for 2-4 hrs in northern prehybridisation soloution. Labelled DNA probes were denatured at 95 °C for 5 mins and added to the blots. All hybridisation steps were carried out in rolling bottles in incubation ovens. Probes were hybridised overnight for at least 16 hrs in the prehybridisation soloution. A standard set of wash soloutions were used. Stringency of washing was acheived by the use of lower salt containing wash buffers. The following wash procedure is outlined as follows
- the method of Feinberg and Vogelstein was used to radioactively label DNA. Briefly, the protocol uses random sequence hexanucleotides to prime DNA synthesis at numerous sites on a denatured DNA template using the Klenow DNA polymerase I fragment. Pre-formed kits were used to aid consistency . 5-100ng DNA fragment (obtained from gel purifcation of PCR or restriction digests) was made up in water,denatured for 5 mins at 95°C with the random hexamers. The mixture was quench cooled on ice and the following were added, 5 ⁇ l [ ⁇ -32P] dATP 3000 Ci/mmol 1 ⁇ l of Klenow DNA polymerase (4U)
- RNA into single stranded cDNA was achieved using the 3' to 5' polymerase activity of recombinant Moloney-Murine Leukemia Virus (M-MLV) reverse transcriptase primed with oligo (dT) and (dN) primers.
- M-MLV Moloney-Murine Leukemia Virus
- dT oligo
- dN oligo primers
- cDNA was synthesised from l ⁇ g poly (A)+ RNA or total RNA was incubated with the following 1.O ⁇ M oligo(dT) primer for total RNA or random hexcamers for mRNA 0.5mM lOmM dNTP mix lU/ ⁇ l RNAse inhibitor (Promega) l.OU/ ⁇ l M-MLV reverse transcriptase in manufacturers supplied buffer
- Samples were prepared for SDS-PAGE by adding 6 times Laemmli electrophoresis sample buffer and boiling for 5 min. After electrophoresis with 16 ⁇ g of protein on a 10% polyacrylamide gel (Laemmli, 1970) the proteins were transferred to PVDF membrane. The blots were washed with PBS and 0.05% Tween (PBS-T). Blocking of the blots occurred in 5% milk powder in PBS-T (60 min, at RT). Blots were incubated with the appropriate primary antibody. Horseradish peroxidase labelled secondary antibody was used to visualise antibody binding by ECL (Amersham, Bucks., UK). Materials used for SDS-PAGE and western blotting were obtained from Biorad (California, USA) unless stated otherwise.
- Table 3 Protein markers of differentiation, detected by Western Blot and/or immunofluorescence.
- RNA examples of vector systems that are to be used in cells to direct the production of stem loop RNA.
- Matzke MA Matzke AJ. Gene silencing in plants: relevance for genome evolution and the acquisition of genomic methylation patterns. Novartis Found Symp. 1998;214:168-80; discussion 181-6. Review.
- Wianny F Zernicka-Goetz M. Specific interference with gene function by double- stranded RNA in early mouse development. Nat Cell Biol. 2000 Feb;2(2):70-5
- Mullis KB Faloona FA. Specific synthesis of DNA in vitro via a polymerase- catalyzed chain reaction. Methods Enzymol. 1987;155:335-50.
- Reubinoff BE Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. 2000 Apr;18(4):399-404.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0118223.7 | 2001-07-26 | ||
GB0118223A GB0118223D0 (en) | 2001-07-26 | 2001-07-26 | Stem loop RNA |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003012082A2 true WO2003012082A2 (en) | 2003-02-13 |
WO2003012082A3 WO2003012082A3 (en) | 2004-06-10 |
Family
ID=9919226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/003409 WO2003012082A2 (en) | 2001-07-26 | 2002-07-25 | Method for modulating stem cell differentiation using stem loop rna |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0118223D0 (en) |
WO (1) | WO2003012082A2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020931A2 (en) * | 2001-09-01 | 2003-03-13 | Galapagos Genomics N.V. | Sirna knockout assay method and constructs |
WO2004085654A2 (en) * | 2003-03-28 | 2004-10-07 | Axordia Limited | Modulation of cell phenotype by inhibitory rna |
WO2006077410A1 (en) * | 2005-01-19 | 2006-07-27 | Systems Biology Laboratory Uk Limited | Method of treatment by administration of rna |
US7196184B2 (en) | 2002-01-22 | 2007-03-27 | Alnylam Europe Ag | Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene |
US7316998B2 (en) | 2004-05-27 | 2008-01-08 | Acceleron Pharma Inc. | Cerberus/Coco derivatives and uses thereof |
US7348314B2 (en) | 2001-10-12 | 2008-03-25 | Alnylam Europe Ag | Compositions and methods for inhibiting viral replication |
US7473525B2 (en) | 2001-01-09 | 2009-01-06 | Alnylam Europe Ag | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7560541B2 (en) | 2002-03-22 | 2009-07-14 | Acceleron Pharma, Inc. | Heart20049410 full-length cDNA and polypeptides |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7833971B2 (en) | 2006-12-08 | 2010-11-16 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
US7893036B2 (en) | 2001-07-12 | 2011-02-22 | University Of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
US8101742B2 (en) | 1999-01-30 | 2012-01-24 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
US9074213B2 (en) | 2001-01-09 | 2015-07-07 | Alnylam Pharmacuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
WO2020097083A1 (en) * | 2018-11-06 | 2020-05-14 | Cellino Biotech, Inc. | Systems for cell control |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997045143A1 (en) * | 1996-05-31 | 1997-12-04 | The National American Red Cross | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
WO1998058958A2 (en) * | 1997-06-25 | 1998-12-30 | University Of Washington | Human jagged polypeptide, encoding nucleic acids and methods of use |
WO1999032619A1 (en) * | 1997-12-23 | 1999-07-01 | The Carnegie Institution Of Washington | Genetic inhibition by double-stranded rna |
WO2000025809A1 (en) * | 1998-10-30 | 2000-05-11 | Smith & Nephew Plc | Compositions comprising notch receptor manipulating agents |
WO2000063364A2 (en) * | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
WO2001003743A1 (en) * | 1999-07-12 | 2001-01-18 | Walter Gehring | Manipulation of tissue or organ type using the notch pathway |
WO2001025422A2 (en) * | 1999-10-07 | 2001-04-12 | Avi Biopharma, Inc. | Antisense compositions and cancer-treatment methods |
WO2001036646A1 (en) * | 1999-11-19 | 2001-05-25 | Cancer Research Ventures Limited | Inhibiting gene expression with dsrna |
WO2002016620A2 (en) * | 2000-08-19 | 2002-02-28 | Axordia Limited | Modulation of stem cell differentiation |
-
2001
- 2001-07-26 GB GB0118223A patent/GB0118223D0/en not_active Ceased
-
2002
- 2002-07-25 WO PCT/GB2002/003409 patent/WO2003012082A2/en not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997045143A1 (en) * | 1996-05-31 | 1997-12-04 | The National American Red Cross | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
WO1998058958A2 (en) * | 1997-06-25 | 1998-12-30 | University Of Washington | Human jagged polypeptide, encoding nucleic acids and methods of use |
WO1999032619A1 (en) * | 1997-12-23 | 1999-07-01 | The Carnegie Institution Of Washington | Genetic inhibition by double-stranded rna |
WO2000025809A1 (en) * | 1998-10-30 | 2000-05-11 | Smith & Nephew Plc | Compositions comprising notch receptor manipulating agents |
WO2000063364A2 (en) * | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
WO2001003743A1 (en) * | 1999-07-12 | 2001-01-18 | Walter Gehring | Manipulation of tissue or organ type using the notch pathway |
WO2001025422A2 (en) * | 1999-10-07 | 2001-04-12 | Avi Biopharma, Inc. | Antisense compositions and cancer-treatment methods |
WO2001036646A1 (en) * | 1999-11-19 | 2001-05-25 | Cancer Research Ventures Limited | Inhibiting gene expression with dsrna |
WO2002016620A2 (en) * | 2000-08-19 | 2002-02-28 | Axordia Limited | Modulation of stem cell differentiation |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8729037B2 (en) | 1999-01-30 | 2014-05-20 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8202980B2 (en) | 1999-01-30 | 2012-06-19 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8101584B2 (en) | 1999-01-30 | 2012-01-24 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8183362B2 (en) | 1999-01-30 | 2012-05-22 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8114851B2 (en) | 1999-01-30 | 2012-02-14 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8168776B2 (en) | 1999-01-30 | 2012-05-01 | Alnylam Pharmaceuticals, Inc. | Method for making a 21 nucleotide double stranded RNA chemically linked at one end |
US8114981B2 (en) | 1999-01-30 | 2012-02-14 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8119608B2 (en) | 1999-01-30 | 2012-02-21 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US9133454B2 (en) | 1999-01-30 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8101742B2 (en) | 1999-01-30 | 2012-01-24 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US9902955B2 (en) | 1999-01-30 | 2018-02-27 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7473525B2 (en) | 2001-01-09 | 2009-01-06 | Alnylam Europe Ag | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US9074213B2 (en) | 2001-01-09 | 2015-07-07 | Alnylam Pharmacuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US9587240B2 (en) | 2001-01-09 | 2017-03-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US8530438B2 (en) | 2001-07-12 | 2013-09-10 | University Of Massachusetts | Vivo production of small interfering RNAs that mediate gene silencing |
US8557785B2 (en) | 2001-07-12 | 2013-10-15 | University Of Massachusetts | In vivo production of small interfering RNAS that mediate gene silencing |
US9850487B2 (en) | 2001-07-12 | 2017-12-26 | University Of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
US9175287B2 (en) | 2001-07-12 | 2015-11-03 | University Of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
US7893036B2 (en) | 2001-07-12 | 2011-02-22 | University Of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
US8232260B2 (en) | 2001-07-12 | 2012-07-31 | University Of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
US10731155B2 (en) | 2001-07-12 | 2020-08-04 | University Of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
WO2003020931A3 (en) * | 2001-09-01 | 2003-11-20 | Galapagos Genomics Nv | Sirna knockout assay method and constructs |
WO2003020931A2 (en) * | 2001-09-01 | 2003-03-13 | Galapagos Genomics N.V. | Sirna knockout assay method and constructs |
US7348314B2 (en) | 2001-10-12 | 2008-03-25 | Alnylam Europe Ag | Compositions and methods for inhibiting viral replication |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
US7763590B2 (en) | 2001-10-12 | 2010-07-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a mutant gene |
US7196184B2 (en) | 2002-01-22 | 2007-03-27 | Alnylam Europe Ag | Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene |
US7846907B2 (en) | 2002-01-22 | 2010-12-07 | Alnylam Pharmaceuticals, Inc. | Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene |
US7560541B2 (en) | 2002-03-22 | 2009-07-14 | Acceleron Pharma, Inc. | Heart20049410 full-length cDNA and polypeptides |
JP2006521109A (en) * | 2003-03-28 | 2006-09-21 | アクソーディア・リミテッド | Modification of cell phenotype by inhibitory RNA |
WO2004085654A2 (en) * | 2003-03-28 | 2004-10-07 | Axordia Limited | Modulation of cell phenotype by inhibitory rna |
WO2004085654A3 (en) * | 2003-03-28 | 2005-03-10 | Axordia Ltd | Modulation of cell phenotype by inhibitory rna |
US7316998B2 (en) | 2004-05-27 | 2008-01-08 | Acceleron Pharma Inc. | Cerberus/Coco derivatives and uses thereof |
US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
US7981857B2 (en) | 2004-05-27 | 2011-07-19 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
WO2006077410A1 (en) * | 2005-01-19 | 2006-07-27 | Systems Biology Laboratory Uk Limited | Method of treatment by administration of rna |
US8796199B2 (en) | 2006-12-08 | 2014-08-05 | Acceleron Pharma, Inc. | Uses of Cerberus and derivatives thereof |
US7833971B2 (en) | 2006-12-08 | 2010-11-16 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
WO2020097083A1 (en) * | 2018-11-06 | 2020-05-14 | Cellino Biotech, Inc. | Systems for cell control |
Also Published As
Publication number | Publication date |
---|---|
WO2003012082A3 (en) | 2004-06-10 |
GB0118223D0 (en) | 2001-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040053869A1 (en) | Stem cell differentiation | |
WO2003012082A2 (en) | Method for modulating stem cell differentiation using stem loop rna | |
US20070087991A1 (en) | Pluripotential stem cells | |
JP4919445B2 (en) | Techniques for proliferation and differentiation of human pluripotent stem cells | |
EP1734112B1 (en) | Method of proliferating pluripotent stem cell | |
US8883501B2 (en) | Method for retarding the differentiation of pluripotent cells | |
CN105586358B (en) | Methods of producing and using multipotent cell populations | |
JP5588405B2 (en) | Rat embryonic stem cells | |
JP2003111588A6 (en) | Techniques for proliferation and differentiation of human pluripotent stem cells | |
JP2014166187A (en) | Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents | |
Menendez et al. | Genetic manipulation of human embryonic stem cells: a system to study early human development and potential therapeutic applications | |
JP2004520046A (en) | Transfection of human embryonic stem cells | |
Chhabra | Derivation of human induced pluripotent stem cell (iPSC) lines and mechanism of pluripotency: historical perspective and recent advances | |
JP5785948B2 (en) | Methods for promoting genomic stability and telomere elongation in embryonic stem cells | |
WO2010069008A9 (en) | A germline competent cell derived from adult tissue | |
Bhartiya et al. | An overview of pluripotent stem cells | |
Li et al. | Leukemia inhibitory factor-expressing human embryonic lung fibroblasts as feeder cells for human embryonic germ cells | |
US8975068B2 (en) | Isolated stem cell comprising a Xic flanking region transgene | |
Boheler et al. | Myocardial aging and embryonic stem cell biology | |
Mcwhir et al. | Gene targeting and embryonic stem cells | |
CN101078012A (en) | Stem cell differentiation | |
US20110008888A1 (en) | Novel Genetic Approaches to Reduce or Inhibit Tumorgenicity of Human Embryonic Stem Cells and Derivatives Following Transplantation | |
Drukker et al. | Genetic engineering of human embryonic stem cells | |
Lavial et al. | Chicken stem cells as a model to generate transgenic chicken: present and perspectives | |
Hohenstein | Dissecting cell fate decisions in human embryonic stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |